Sorry to but in to your discussion but just a couple of thoughts. InterMune (a while back) created an early access program for Pirfenidone where a lottery system was used as the entry criteria. Also Actimmune was available (granted off-label) while the company was actively recruiting for the (since discontinued) INSPIRE study. One motivation to enroll in a trial rather then CU program could be the drug is provided free of charge for some period after the study. Yeah I guess it slows enrollment somewhat but there is still incentive for some and you get some of the benefits of getting the drug out there. Just my 2 cents.
Market Data 
Markets 
AI
